Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Pharmacology

Background:

• Polycystic ovary syndrome (PCOS) is associated with endothelial dysfunction.
• Metformin has shown potential in improving endothelial reactivity in normal-weight PCOS subjects.
• The precise mechanisms of metformin's vascular effects in PCOS require further investigation.

Purpose of the Study:

• To investigate the mechanisms by which metformin influences vascular function in normal-weight PCOS patients.
• To assess the impact of metformin on endothelial reactivity and its correlation with endocrine-metabolic parameters.
• To elucidate the role of hormonal changes in metformin's vascular benefits for PCOS.

Main Methods:

• A study involving thirteen normal-weight, normoinsulinemic, and normolipemic PCOS women.
• Treatment with metformin (1000 mg/day) for six months.
• Assessment of endothelial function via brachial artery flow-mediated dilatation (FMD) and correlation with endocrine-metabolic features.

Main Results:

• Metformin significantly reduced testosterone and 17-hydroxyprogesterone levels.
• No significant changes were observed in gluco-insulinemic parameters.
• Concomitant significant increases in basal vessel diameter and flow-mediated dilatation (FMD) indicated improved endothelial function.

Conclusions:

• Metformin positively impacts altered vascular reactivity in normoinsulinemic PCOS subjects, a marker of cardiovascular risk.
• The improvement in endothelial function appears to be mediated by hormonal changes, particularly reduced hyperandrogenism.
• While hormonal effects are highlighted, a direct impact of metformin on the endothelium cannot be ruled out.